Skip to main content
. 2013 Sep 17;8(9):e74869. doi: 10.1371/journal.pone.0074869

Figure 3. Effects of intraperitoneal (IP) administration of Wy-14643 on plasma metabolites.

Figure 3

β-hydroxybutyrate (BHB) (A) and non-esterified fatty acids (NEFA) (B) levels were assessed 45 min before (baseline), 35 and 70 min after treatment (Wy-14643, 40 mg/kg/ml) and 3g HFD test meal. ** Significant difference compared to vehicle (P < 0.01; Wilcoxon Signed Ranks Test, data are presented as median with 25th/75th percentiles.